Pacific Biosciences
PACB
143 hedge funds and large institutions have $592M invested in Pacific Biosciences in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 29 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
2% less capital invested
Capital invested by funds: $607M → $592M (-$14.4M)
1.56% less ownership
Funds ownership: 76.85% → 75.28% (-1.6%)
3% less funds holding
Funds holding: 148 → 143 (-5)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
52% less call options, than puts
Call options by funds: $697K | Put options by funds: $1.45M
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$26.8M |
| 2 |
GCM
Glenview Capital Management
New York
|
+$19.4M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$17.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.2M |
| 5 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$28.4M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$26.2M |
| 3 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
-$19M |
| 4 |
VI
Versor Investments
New York
|
-$11.3M |
| 5 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$9.34M |
PACB Hedge Fund Activity: Q4 2019 in Review
143 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2019, worth a combined $592M — down 2.4% from $607M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PACB and 24 opened new positions — a net loss of 5 holders — while 41 trimmed existing stakes and 54 added.
The largest buyer was Capital International Investors, opening a new position worth an estimated $26.8M. The largest seller was Alpine Associates Management, exiting entirely with an estimated $28.4M sold.
- 143 institutional investors held Pacific Biosciences (PACB) as of Q4 2019, down from 148 in Q3 2019.
- Funds reported $592M of Pacific Biosciences stock for Q4 2019, down 2.4% quarter-over-quarter.
- 24 funds opened new Pacific Biosciences positions in Q4 2019 and 29 closed out, a net change of -5 holders.
- The largest Pacific Biosciences buyer in Q4 2019 was Capital International Investors, an estimated $26.8M added.
- The largest Pacific Biosciences seller in Q4 2019 was Alpine Associates Management, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2019.